Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars

oncology insights Oncology Insights: 2024 Rewind January 16, 2025 Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these...

Lead author David Eckwright shares more about the study “Real-World Extended Dosing Assessment for Eye(s) new to Faricimab-svoa Therapy.”

See our history Our teams have poured energy, integrity and compassion into transforming pharmacy solutions, turning barriers into breakthroughs. Breadcrumb Home Who we are Our history Tab 1 2021 –...

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management

Hero headline Forward copy that anchors in the key themes of our campaign: we are an organization you can trust, with solutions built for every plan, and people who will work to do what is right...

As the efficacy and cost of these therapies become clear, so is the need for thoughtful managed care strategies, according to Prime Therapeutics thought leaders

New report highlights value-based contract solution and analysis of top 10 drug classes impacting Medicaid pharmacy net trend

Perspectives High-Cost Therapy Profile: June 2024 Detailed information about Imetelstat Intravenous (IV) June 14, 2024 Oncology Imetelstat Intravenous (IV) Geron Proposed indications For the...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

publications High-Cost Therapy Profile: February 2025 Revakinagene taroretcel Ocular implant | Neurotech Pharmaceuticals, Inc. Ophthalmology February 13, 2025 Proposed indications Macular...

Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 Neurology Eladocagene Exuparvovec Intrapuraminal PTC Therapeutics, Inc. Proposed indications...

publications 2024 Employer Market Insights Report June 28, 2024 Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication,...

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Eyebrow High-Cost Therapy Profile: August 2024 Detailed information about intravenous (IV) linvoseltamab August 15, 2024 Oncology Linvoseltamab, intravenous (IV) Regeneron Pharmaceuticals ...

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...